U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 31 results

Status:
US Approved Rx (2018)
First approved in 2007

Class (Stereo):
CHEMICAL (RACEMIC)



Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothel...
Status:
US Approved Rx (2018)
First approved in 1995

Class (Stereo):
CHEMICAL (RACEMIC)



Carvedilol competitively blocks β1, β2 and α1 receptors. The drug lacks sympathomimetic activity and has vasodilating properties that are exerted primarily through α1-blockade. Animal models indicate that carvedilol confers protection against myocard...
Status:
US Approved Rx (2003)
First approved in 1992

Class (Stereo):
CHEMICAL (RACEMIC)



Sotalol has both beta-adrenoreceptor blocking and cardiac action potential duration prolongation antiarrhythmic properties. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2...
Status:
US Approved Rx (2024)
First approved in 1992

Class (Stereo):
CHEMICAL (RACEMIC)


Conditions:

Bisoprolol is a cardioselective beta1-adrenergic blocking agent. It lower the heart rate and blood pressure and may be used to reduce workload on the heart and hence oxygen demands. This results in a reduction of heart rate, cardiac output, systolic ...
Status:
US Approved Rx (2000)
First approved in 1988

Class (Stereo):
CHEMICAL (RACEMIC)



Carteolol is a nonselective beta-adrenoceptor blocking agent for ophthalmic use. It has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be u...
Status:
US Approved Rx (2022)
First approved in 1986

Class (Stereo):
CHEMICAL (RACEMIC)



Esmolol (trade name Brevibloc) is a cardioselective beta1 receptor blocker with rapid onset, a very short duration of action, and no significant intrinsic sympathomimetic or membrane stabilizing activity at therapeutic dosages. Esmolol decreases the ...
Status:
US Approved Rx (2009)
First approved in 1985

Class (Stereo):
CHEMICAL (RACEMIC)



Betaxolol or SL 75212, (± )-1-(isopropylamino)-3-(p-(cyclopropylmethoxyethyl-phenoxy)2-propranol, is a potent cardioselective beta1-adrenoceptor antagonist devoid of intrinsic sympathomimetic activity with very weak local anaesthetic properties. Oral...
Status:
US Approved Rx (2021)
First approved in 1984

Class (Stereo):
CHEMICAL (MIXED)


Conditions:

Labetalol is a blocker of both alpha- and beta-adrenergic receptors that is used as an antihypertensive. It may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. The capacity of labetalol HCl ...
Status:
US Approved Rx (1995)
First approved in 1984

Class (Stereo):
CHEMICAL (RACEMIC)



Acebutolol is a cardioselective, beta-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. Acebutolol is marketed under the trade names Sectral, Prent. Acebutolol is...
Status:
US Approved Rx (1994)
First approved in 1982

Class (Stereo):
CHEMICAL (RACEMIC)



Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-...